Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|February 26, 2019
Intelligent Dose Design
Author(s)Catalent
Catalent Pharma Solutions offers its partners end-to-end solutions, from early drug product development, formulation and drug delivery technologies, to manufacturing and global clinical supply services.
Advertisement
Catalent has a broad range of experience and expertise in early-phase development, which sees the company support the introduction of more than 150 new products to market every year. From its three early-phase drug development centres of excellence in Nottingham, UK, Somerset, New Jersey, and San Diego, California, Catalent offers partners its formulation and development experience, and a wide range of tools and technologies to create innovative, intelligent dose forms to overcome each molecule’s individual challenges, while making better products for patients.
Catalent’s multi-award-winning OptiForm® Solution Suite platform can assist in the development of oral dose forms that can improve a drug’s clinical efficacy and commercial success. OptiForm Solution Suite is fast, flexible and fact-based, combining the broadest selection of enabling technologies to ensure the right decisions are made at each stage of development.
Designed to make it easier and faster for small and mid-sized innovators to develop better treatments, OptiForm Solution Suite includes a comprehensive range of candidate screening tools, Absorption, Distribution, Metabolism and Excretion (ADME) considerations, and in silico Drug Metabolism and Pharmacokinetics (DMPK) modelling, as well as additional bioavailability enhancing tools to provide materials for cGLP toxicological studies, and on to first-in-human studies.
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement